1. K. Inoue, H. Fujisawa, Y. Sasaki, T. Nishimura, I. Nishimura, Y. Inoue, M. Yokota, T. Masuda, F. Ueda, Y. Shibata, K. Kimura, K. Inoue, Y. Komiya and J. Nishioka,Pharmacological properties of the new non-steroidal anti-inflammatory agent etodolac. Arzneim.-Forsch.41, 228–235 (1991).
2. E. S. Ferdinandi, M. N. Cayen and C. Pace-Asciak,Disposition of etodolac, other anti-inflammatory pyranoindole-1-acetic acids and furobufen in normal and adjuvant arthritic rats. J. Pharmacol. Exp. Ther.220, 417–426 (1982).
3. L. G. Humber,Etodolac: The chemistry, pharmacology, metabolic disposition, and clinical profile of a novel anti-inflammatory pyranocarboxylic acid. Med. Res. Rev.7, 1–28 (1987).
4. K. Inoue, A. Motonaga, T. Nishimura, M. Yokota, N. Miki, H. Fujisawa, F. Ueda, Y. Shibata and K. Kimura,Mechanism of anti-inflammatory action of etodolac. Arzneim.-Forsch.41, 235–239 (1991).
5. R. R. Martel, J. Klicius and G. Metcalf,Effect of etodolac on articular and bone pathology associated with adjuvant arthritis in rats: A comparison with aspirin and naproxen. Agents and Actions14, 257–264 (1984).